FiveThirty Foundation

Let it be known: FiveThirty stands by its own strength and funding, and by its own strength alone shall it endure. No tribute, no offering, nor promise of value shall buy its soul. Never shall dominion over it be traded, nor its honor be compromised. It is, and shall forever remain, sovereign.

Access to essential medicine is a fundamental human right. Today, this right is denied to millions by a system that prioritizes patents over patients. The knowledge to create life saving drugs is intentionally obscured, locked behind legal and financial barriers that serve profit, not people. This is a profound moral and systemic failure. We are here to correct it.

Our response is not to negotiate with this system, but to render it obsolete. We are building a new paradigm for pharmaceutical discovery. By applying advanced AI to public chemical and medical data, our Retrosynthesis models reverse-engineer the pathways to essential medications. Our singular focus is to identify and validate the most direct, efficient, and low-cost methods of synthesis, stripping away the artificial complexity that sustains exorbitant prices.

The knowledge we generate belongs to humanity. We will operate on a principle of radical transparency, publishing our findings openly and making our core models accessible. Our goal is to empower a global network of manufacturers, researchers, and healthcare providers with the tools to produce medication locally and affordably.

We reject the premise that human health is a market. We are committed to dismantling the artificial scarcity that defines modern pharmaceuticals. The path is difficult and the opposition is formidable. Our resolve is stronger. We are driven by a singular, non-negotiable mission that insulates us from short-term commercial pressures and distractions.

We are assembling a focused team of young scientists, engineers, and coders. If you are driven to solve this critical challenge and are determined to succeed in this endeavor with us, we invite you to join.

— Amirhossein Azhinehfar, Co-Chair, 5:30